[{"address1": "171 Oyster Point Boulevard", "address2": "Suite 400", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 489 9000", "website": "https://www.surrozen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.", "fullTimeEmployees": 42, "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig C. Parker M.B.A.", "age": 61, "title": "CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 825320, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles  Williams", "age": 43, "title": "CFO, COO & Corporate Secretary", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 611028, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Li  Yang Ph.D.", "age": 54, "title": "Executive Vice President of Research", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 535463, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. K. Christopher  Garcia Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roeland  Nusse Ph.D.", "age": 73, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1950, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Calvin  Kuo M.D., Ph.D.", "title": "Co-Founder & Member of Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Esther  Jhun", "title": "Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.0, "open": 11.46, "dayLow": 11.46, "dayHigh": 13.4399, "regularMarketPreviousClose": 11.0, "regularMarketOpen": 11.46, "regularMarketDayLow": 11.46, "regularMarketDayHigh": 13.4399, "beta": 0.941, "forwardPE": -3.0338378, "volume": 62032, "regularMarketVolume": 62032, "averageVolume": 17557, "averageVolume10days": 41800, "averageDailyVolume10Day": 41800, "marketCap": 43086304, "fiftyTwoWeekLow": 4.5, "fiftyTwoWeekHigh": 16.19, "fiftyDayAverage": 9.91426, "twoHundredDayAverage": 10.16485, "currency": "USD", "enterpriseValue": 7487330, "floatShares": 1551664, "sharesOutstanding": 3205850, "sharesShort": 44460, "sharesShortPriorMonth": 49173, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0139, "heldPercentInsiders": 0.016929999, "heldPercentInstitutions": 0.76928, "shortRatio": 3.4, "shortPercentOfFloat": 0.0187, "impliedSharesOutstanding": 3273340, "bookValue": 1.891, "priceToBook": 7.107298, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -53449000, "trailingEps": -22.49, "forwardEps": -4.43, "pegRatio": -0.03, "lastSplitFactor": "1:15", "lastSplitDate": 1702512000, "enterpriseToEbitda": -0.209, "52WeekChange": 1.088578, "SandP52WeekChange": 0.30908787, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SRZN", "underlyingSymbol": "SRZN", "shortName": "Surrozen, Inc.", "longName": "Surrozen, Inc.", "firstTradeDateEpochUtc": 1610375400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f300e438-31d2-353a-a98a-8e2cc4bb3308", "messageBoardId": "finmb_401948183", "gmtOffSetMilliseconds": -14400000, "currentPrice": 13.4399, "targetHighPrice": 33.0, "targetLowPrice": 33.0, "targetMeanPrice": 33.0, "targetMedianPrice": 33.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 37765000, "totalCashPerShare": 11.78, "ebitda": -35835000, "totalDebt": 2166000, "quickRatio": 6.665, "currentRatio": 6.959, "debtToEquity": 35.731, "returnOnAssets": -0.43030998, "returnOnEquity": -1.74899, "freeCashflow": -17459876, "operatingCashflow": -31801000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-01"}]